FRAMINGHAM, Mass.– Definitive Healthcare Corp. (“Definitive Healthcare”), an industry leader in healthcare commercial intelligence, today announced that it plans to commence the roadshow for its proposed initial public offering of its Class A common stock. Definitive Healthcare is offering 15,555,555 shares of its Class A common stock. The initial public offering price is expected to be between $21 and $24 per share pursuant to a registration statement on Form S-1 previously filed with the United States Securities and Exchange Commission (the “SEC”). Definitive Healthcare expects to grant the underwriters a 30-day option to purchase up to an additional 2,333,333 shares of its Class A common stock at the initial public offering price.
Definitive Healthcare has applied to list its Class A common stock under the ticker symbol “DH” on the Nasdaq Global Select Market. Definitive Healthcare intends to use a portion of the proceeds to purchase limited liability company interests and repurchase shares of its Class A common stock.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as lead joint book-running managers and representatives of the underwriters for the proposed offering. Morgan Stanley & Co. LLC and Barclays Capital Inc. are acting as joint book-running managers and are also representatives of the underwriters for the proposed offering. Credit Suisse Securities (USA) LLC and Deutsche Bank Securities Inc. are acting as book-runners for the proposed offering. Canaccord Genuity LLC, Raymond James & Associates, Inc., Stifel, Nicolaus & Company, Incorporated, Drexel Hamilton, LLC and Loop Capital Markets LLC are acting as co-managers.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the proposed offering may be obtained from the SEC at www.sec.gov, and copies of the preliminary prospectus may be obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectuseq_fi@jpmorganchase.com; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at prospectus@morganstanley.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847 or by at email at barclaysprospectus@broadridge.com.
A registration statement on Form S-1 relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
